FindTrial
Sign In

A study about the role of exosome microRNA/DNA by high-throughout sequencing in evaluating the prognosis of prostate cancer patients

A study about the role of exosome microRNA/DNA by high-throughout sequencing in evaluating the prognosis of prostate cancer patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-POC-17012593
Enrollment
Unknown
Registered
2017-09-06
Start date
2017-10-01
Completion date
Unknown
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Case series :Nil

Sponsors

Nanfang Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. The patients have been histologically confirmed as PCa by pathologists; 2. Cases received no prostate cancer relevant therapy; 3. Cases with complete clinical information.

Exclusion criteria

Exclusion criteria: Patients cannot complete the follow-up

Design outcomes

Primary

MeasureTime frame
Expression profile of exosome microRNA;The mutation profile of exosome DNA;microRNA expression profile of prostate tissue ;Exon mutation profileof prostate cancer tissue;—

Countries

China

Contacts

Public ContactWei Qiang

Nanfang Hospital

weiqiang0915@163.com+86 020 61641114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026